Background: Women with epithelial ovarian cancer (OC) have a higher chance to benefit from poly (ADP-ribose) polymerase inhibitor (PARPi) therapy if their tumor has a somatic or hereditary BRCA1/2 pathogenic variant. Current guidelines advise BRCA1/2 genetic predisposition testing for all OC patients, though this does not detect somatic variants. We assessed the feasibility of a workflow for universal tumor DNA BRCA1/2 testing of all newly diagnosed OC patients as a prescreen for PARPi treatment and cancer predisposition testing. Methods: Formalin-fixed paraffin-embedded tissue was obtained from OC patients in seven hospitals immediately after diagnosis or primary surgery. DNA was extracted, and universal tumor BRCA1/2 testing was then performed in a single site. Diagnostic yield, uptake, referral rates for genetic predisposition testing, and experiences of patients and gynecologists were evaluated. Results: Tumor BRCA1/2 testing was performed for 315 (77.6%) of the 406 eligible OC samples, of which 305 (96.8%) were successful. In 51 of these patients, pathogenic variants were detected (16.7%). Most patients (88.2%) went on to have a genetic predisposition test. BRCA1/2 pathogenic variants were shown to be hereditary in 56.8% and somatic in 43.2% of patients. Participating gynecologists and patients were overwhelmingly positive about the workflow. Conclusions: Universal tumor BRCA1/2 testing in all newly diagnosed OC patients is feasible, effective, and appreciated by patients and gynecologists. Because many variants cannot be detected in DNA from blood, testing tumor DNA as the first step can double the identification rate of patients who stand to benefit most from PARP inhibitors.
with defective homologous recombination mediated repair, especially BRCA1/2 defects (9) (10) (11) (12) (13) (14) . An estimated 18%-24% of patients with OC carry a BRCA1/2 pathogenic variant in their tumor, often in the context of an inherited germline BRCA1/2 variant. It is estimated that of the patients with a tumor BRCA1/2 variant, 54%-74% represent hereditary defects and 27%-46% somatic defects that are present in the tumor only (5) (6) (7) (8) .
Because a tumor BRCA1/2 test detects both hereditary and somatic BRCA1/2 variants, we developed a new workflow starting with universal tumor DNA BRCA1/2 testing in newly diagnosed OC patients. This workflow is based on our technical approach using single-molecule molecular inversion probe (smMIP) enrichment followed by next-generation sequencing (NGS) and allows rapid and reliable detection of both hereditary and somatic aberrations affecting BRCA1/2 in DNA derived from formalin-fixed paraffin-embedded (FFPE) tissue of OC (15) .
The new universal tumor BRCA1/2 workflow has three key features. First, it detects many more patients who are eligible for PARPi therapy than conventional genetic predisposition testing of DNA from blood. Individuals can subsequently decide whether to continue with testing for a heritable BRCA1/2 variant. Second, testing tumor DNA effectively serves as a prescreen to tailor genetic counseling to those with a high a priori risk of a hereditary pathogenic variant. Third, by focusing on treatment options, the strategy may improve uptake of BRCA1/2 genetic predisposition in patients with OC.
In this study, the novel workflow of universal tumor DNA BRCA1/2 testing was implemented in seven hospitals. Its feasibility, effectiveness, and appreciation were evaluated by uptake, diagnostic yield, and referral rates for subsequent genetic counseling. The experiences of patients and gynecologists were systematically assessed.
Methods

Study Population
In this multicenter, observational cohort study, seven hospitals (two university and five regional) implemented universal tumor DNA BRCA1/2 testing in standard care between October 2015 and June 2017. Universal tumor BRCA1/2 testing was performed on tumor DNA from OC obtained by a diagnostic biopsy or a primary staging or cytoreductive surgery for OC. In a few cases, cells obtained from ascites aspiration were analyzed.
To measure uptake, OC patients (excluding borderline) were identified through a search of the nationwide registry of histoand cytopathology (PALGA) (16) . For all patients, referral for genetic counseling and genetic predisposition testing to the two genetic centers in the region and vital status were checked manually up to August 2018 (Supplementary Figure 1 , available online). This study was approved by the privacy committee and the scientific board of PALGA and the medical ethical committee (NL 52165.091.15, 2015-1579). As required, written informed consent was obtained from the patients participating in the interviews. As part of diagnostics, patients provided oral informed consent for genetic testing.
Procedures
Pathologists were instructed to submit FFPE OC samples for centralized tumor DNA BRCA1/2 testing at the Radboud University Medical Center. Quality and quantity of tumor DNA (20% neoplastic cells) were evaluated centrally. Tumor DNA testing was performed with smMIP-based NGS of BRCA1/2, multiplex ligation-dependent probe amplification (MLPA), and methylation-specific MLPA of BRCA1 (15) . Pathogenic and likely pathogenic variants (subsequently pathogenic variants) in BRCA1/2 were reported to the pathologist and gynecologist.
Gynecologists discussed the tumor DNA BRCA1/2 test and its results with the patient and were instructed to refer consenting patients with a tumor BRCA1/2 variant for genetic counseling if desired. Information for professionals and short videos for patients considering the difference between DNA testing in blood and in tumor tissue were provided after a positive tumor DNA BRCA1/2 test result and before genetic testing (see www.cancergenetics.eu).
Outcomes
The feasibility and effectiveness of the universal tumor BRCA1/2 workflow was assessed by its diagnostic yield, uptake of tumor DNA BRCA1/2 testing by pathologists, rate of successful testing, turnaround times, and referral rates for genetic counseling.
The appreciation of patients was assessed with semistructured telephone interviews in a random sample of patients with somatic variants, germline variants, or without any variant. The appreciation of gynecologists in participating hospitals was assessed by a questionnaire.
Statistical Analysis
Patient groups were compared using Mann-Whitney U tests and Fisher exact tests. Bonferroni correction was applied when assessing differences between three patient groups. P values less than .05 (two-tailed) were considered statistically significant. Analyses were performed with R software (17) . (Figure 1 ). During the active implementation of universal tumor testing, uptake increased from 58.8% in the first 4 months of implementation to 79.7% in the last 4 months (Figure 2 Patients with pathogenic hereditary BRCA1/2 variants were younger at OC diagnosis than patients without any tumor BRCA1/2 pathogenic variants (median 57 years, IQR ¼ 52-65 years vs median 66 years, IQR ¼ 57-73 years, respectively, P ¼ .009) ( Table 4 ; Supplementary Figure 2 , available online). Patients with pathogenic hereditary BRCA1/2 variants were more likely to have high-grade serous OC than patients without tumor variants (84.0% vs 61.0%, P ¼ .09), with no statistically significant difference between patients with a BRCA1 or BRCA2 variant (92.3% vs 75.0%, P ¼ .26; Table 2 ). Based on their personal and family history of cancer, 13 (52.0%) patients with pathogenic hereditary BRCA1/2 variants (69.2% BRCA1 and 33.3% BRCA2, P ¼ .12) already complied with National Comprehensive Cancer Network (NCCN) criteria for BRCA1/2 testing before their OC diagnosis (Table 2) , suggesting their tumors could have been prevented by earlier genetic testing in relatives and presymptomatic cascade testing.
Results
Uptake
Two tumors with a somatic pathogenic BRCA1/2 variant additionally harbored multiple other somatic variants in BRCA1 and/or BRCA2. In both tumors, a somatic pathogenic POLE variant was detected as the driver genetic defect.
Referral for Genetic Counseling and BRCA1/2 Genetic Predisposition Testing
Of 51 patients with a tumor BRCA1/2 pathogenic variant, 45 (88.2%) were referred for genetic counseling, of whom 44 chose genetic predisposition testing and 1 patient postponed her genetic counseling to a later time (Table 1 ). In total, six patients were not referred, of whom four died shortly after diagnosis. Two patients with a pathogenic BRCA1/2 variant in their OC were erroneously not referred. Of 254 patients without tumor BRCA1/2 pathogenic variants, 34 (13%) were referred for genetic counseling and genetic predisposition testing, including two referrals indicated by a first-degree relative with OC. Of 315 patients with a tumor DNA BRCA1/2 test, 275 (87.3%) were either appropriately referred (55 of 63) or not referred (220 of 252) ( Table 1) . The appropriate referral rates remained stable over time, and the number of unjustified referrals-no tumor mutation and no suspected family history-decreased as fewer patients were referred before their negative tumor test result was available (Figure 2 ).
Patient Experiences
Of 18 invited patients, 13 (72.2%) consented to the telephone interview. This included four (30.8%) patients with hereditary, three (23.1%) with somatic, and six (46.2%) without BRCA1/2 pathogenic variants. Two patients (one with a somatic variant and one without a tumor BRCA1/2 pathogenic variant) were unaware of their tumor test. However, all appreciated that the tumor test was done, and they were satisfied with the amount and nature of the information provided by their physician. The patients specifically valued the speed with which the procedure allowed them to obtain relevant knowledge on heredity. Patients' suggestions for improvement focused on reduction of waiting time after referral for genetic counseling to evaluate heredity of the identified tumor BRCA1/2 variant immediately.
Gynecologist Experiences
Questionnaire responses were received from 18 of 41 (43.9%) invited gynecologists. Fifteen (83.3%) were mostly or completely positive about universal tumor DNA BRCA1/2 testing, and one (5.6%) was mostly negative. Gynecologists indicated that the workflow could be further improved by quicker tumor test results (5 of 18), better communication of the tumor test results to the gynecologist (11 of 18), and more available information for patients (10 of 18) . Sixteen gynecologists (88.9%) agreed with the statement that the gynecologist is the most suited physician to discuss tumor DNA BRCA1/2 testing, but one (5.6%) was of the opinion that tumor DNA BRCA1/2 testing should be performed only after formal clinical genetic counseling. The majority (14 of 18, 77.8%) of the gynecologists considered the test turnaround time to be adequate, but several gynecologists stated that they had to schedule an additional appointment to discuss the outcome. Explaining tumor DNA BRCA1/2 testing and reporting negative results took less than 5 minutes for all responding gynecologists, and one-half (9 of 18) needed more than 5 minutes to explain the relevance of a detected variant. The gynecologists perceived that the understanding of patients was considered good before testing in 55.6%. After disclosure and discussion of test results, this increased to 86.1%.
Discussion
Universal tumor DNA BRCA1/2 testing in OC patients was shown to be feasible in daily practice, and patients and gynecologists were overwhelmingly positive about this workflow. Universal tumor testing was performed in 77.6% of the patients and yielded 16.7% pathogenic BRCA1/2 variants in the tumor DNA, whereas a pathogenic variant would have been detected in only 9.5% of patients with universal genetic predisposition testing. Hence, the universal tumor BRCA1/2 workflow identified twice as many patients for PARPi therapy than conventional genetic predisposition testing of DNA from blood could have detected.
PARPi therapies are becoming more and more important to improve the generally poor prognosis of OC (14, 18) . Under current universal OC genetic predisposition testing guidelines, up to 90.5% of patients would receive two genetic tests because they are negative for a hereditary variant and would need a subsequent tumor test to identify somatic BRCA1/2 variants. The universal tumor testing workflow is more effective and reduces the number of tests by 38.7% because in about 16.7% of the patients, subsequent heredity genetic counseling and a blood test are needed. Furthermore, tumor BRCA1/2 status is available shortly after OC diagnosis, which is advantageous now that maintenance treatment with PARPi after first-line chemotherapy has been shown to be effective (14) .
By focusing on treatment options, the strategy may improve uptake of BRCA1/2 testing in patients with OC. In our study, we showed that after an implementation learning period of 6 months, 70.4% of the OC followed the intended workflow: 81.6% of newly diagnosed OC patients received universal tumor DNA BRCA1/2 testing, and 86.3% of those who tested positive received genetic counseling and testing. The performance of the workflow can likely be generalized to each hospital setting because no difference existed between university and community hospitals. The high uptake may also be reached by conventional genetic predisposition testing because active implementation of universal testing yielded uptake rates up to 74%-90% (19) (20) (21) , which is far beyond reported uptake of universal BRCA1/2 genetic predisposition testing in OC in the United States and Canada of only 10%-30% (22, 23) . However, the waiting lists for genetic counseling and genetic predisposition testing may stagnate the increasing uptake (24) . Testing tumor DNA will effectively serve as a prescreen to tailor genetic counseling to those with a high a priori risk of a hereditary pathogenic variant. From our data, we conclude that it will diminish by sixfold the number of patients needing genetic counseling and genetic predisposition testing.
In this study, tumor BRCA1/2 pathogenic variants were identified in 16.7% of OCs. This rate is in line with previously reported rates of 18%-24% (6) (7) (8) . The proportion of pathogenic hereditary BRCA1/2 variants of 56.8% is similar to rates found in another recent cohort (54%) but low compared with 62%-74% in other studies (5) (6) (7) (8) . Possible explanations can be low prevalence of founder mutations and reduction of BRCA1/2-associated tumors due to relatively high uptake of predictive genetic testing and subsequent preventive measures in our population (25) .
It is essential that the test on FFPE tumor material as a prescreen for genetic counseling and genetic predisposition testing is equally reliable as genetic predisposition testing on DNA derived from peripheral blood lymphocytes. Our validated approach with smMIP-based NGS and MLPA detects all known pathogenic hereditary BRCA1/2 variants (15). During our study, the CNV analysis by MLPA was impossible for 3.1% OCs with successful smMIP-based NGS, which leads to a minor decrease in sensitivity of the tumor test. However, exon deletions and duplications form a minority of the pathogenic hereditary variants, and only two somatic exon deletions or duplications were present in the 297 samples that could be evaluated for these types of variants. Overall, we conclude that it is safe and feasible to replace BRCA1/2 genetic predisposition testing by BRCA1/2 tumor DNA testing as a prescreen for BRCA1/2 genetic predisposition testing when performed in an accredited genetic diagnostic laboratory after rigorous validation of the assay.
A strength of this study is that the novel workflow was implemented in the daily clinical practice of multiple centers through which realistic uptake rates could be assessed. However, this limited the possibility to assess why patients did not undergo a tumor test or predisposition testing. The uptake of cancer predisposition testing may therefore be even higher because some patients may have received testing at other genetic centers.
In conclusion, universal BRCA1/2 tumor testing in all new OC patients simultaneously facilitates treatment and genetic screening purposes and is very well appreciated by participating patients and gynecologists. It is more effective than current guideline advice with universal genetic predisposition testing because it reduces the number of tests and consultations needed and provides information on tumor BRCA1/2 variants shortly after diagnosis, enabling personalized treatment choices with PARPi. It also reaches patients with somatic variants and patients who are underrepresented in clinical genetic counseling and genetic predisposition testing, such as patients with a low educational level and non-Caucasian background (26) . Universal tumor DNA BRCA1/2 testing is a robust and suitable option that effectively and efficiently increases the opportunity for targeted treatment in patients and cancer prevention in relatives.
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